Treatment with Huperzine A Improves Cognition in Vascular Dementia Patients

Xu, Zhi‐Qiang; Liang, Xiaomin; Juan-Wu,; Zhang, Yuan-Feng; Zhu, Chunxia; Jiang, Xiaojiang

doi:10.1007/s12013-011-9258-5

Cited by 48 publications

(30 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All selected trials were randomized. One trial [43] was single-blind, and the other [4] was double-blind. The description of the trial characteristics and demographics of the participants in the studies were also showed in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Augmentation of cholinergic neurotransmission with the use of cholinesterase inhibitors (ChE-Is) produces a modest improvement in cognitive function for some patients [2, 3]. VD is a type of dementia caused by a variety of cerebral vascular diseases such as cerebral hemorrhage, cerebral infarction, and subarachnoid hemorrhage [4]. More interestingly, cholinergic agents, including ChE-Is, have shown considerable benefits in VD therapy [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis

Xing

Zhu

Zhang

et al. 2014

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The objective of our study was to perform an updated meta-analysis of placebo-controlled RCTs of Huperzine A (Hup A) on patients with Alzheimer's disease (AD) and vascular dementia (VD), in order to provide the basis and reference for clinical rational drug use. The primary outcome measures assessed were minimental state examination (MMSE) and activities of daily living scale (ADL). Eight AD trials with 733 participants and two VD trials with 92 participants that met our inclusion criteria were identified. The results showed that Hup A could significantly improve the MMSE and ADL score of AD and VD patients, and longer durations would result in better efficacy for the patients with AD. It seemed that there was significant improvement of cognitive function measured by memory quotient (MQ) in patients with AD. Most adverse effects in AD were generally of mild to moderate severity and transient. Compared to the patients with AD, Hup A may offer fewer side effects for participants with VD in this study. Therefore, Hup A is a well-tolerated drug that could significantly improve cognitive performance in patients with AD or VD, but we need to use it with caution in the clinical treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis

Xing

Zhu

Zhang

et al. 2014

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In fact, Huperzine A has been used for treating AD and mild memory deficits since 1994 in the China [55, 56]. In a randomized, double-blinded placebo-controlled clinical trial with the participation of 78 patients who have mild to moderate VaD, Huperzine A treatment significantly improved the cognitive functions in these patients [57]. Furthermore, both animal and human safety evaluations have demonstrated that Huperzine A is safe [58].…”

Section: Therapeutic Implications For Vci With Traditional Chinesementioning

confidence: 99%

Vascular Contributions to Cognitive Impairment and Treatments with Traditional Chinese Medicine

Zhou

Cui

Tseng

et al. 2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The prevalence of cognitive impairment and dementia caused by cerebrovascular disease is likely to increase with the global aging population. Vascular contributions to cognitive impairment and dementia (VCID) is a wide spectrum term used to include a diverse heterogeneous group of cognitive syndromes with vascular factors regardless of the cause of pathogenesis. VCID ranges from mild cognitive impairment to full-blown dementia with vascular dementia (VaD) as the most severe stage. It is further complexed by the coexistence of other forms of dementia such as Alzheimer's disease (AD). Recent researches in the functions of the neurovascular unit (NVU) suggest that dysfunction of the NVU might be the cause of primary vascular events in the brain that leads to further neurodegeneration. In this review, we have briefly summarized various forms of VCID. There is currently no standard therapy for VCID or dementia. Given the fact that Traditional Chinese Medicine (TCM) has gained popularity worldwide, we also reviewed recent scientific and clinical findings on various antidementia TCM for the treatment of VCID, including Salvia miltiorrhiza, Huperzia serrata, Ligusticum chuanxiong, Ginkgo biloba, Panax ginseng, and also TCM formula Sailuotong capsule (SLT) and Fufangdanshen tablets (FFDS).

show abstract

“…Recently an RCT of older adults (60–80 years old) with VaD showed huperzine A improved activities of daily living (ADLs) and cognitive tests (MMSE & clinical dementia rating). 51 However, in the US, a larger clinical trial showed only a modest effect of high dosage huperzine A (400 μg twice daily) on cognition. 52 Huperzine A was well tolerated with the most common side effect being nausea.…”

Section: Huperzine Amentioning

confidence: 99%

Natural Products and Supplements for Geriatric Depression and Cognitive Disorders: An Evaluation of the Research

Varteresian

Lavretsky²

2014

Curr Psychiatry Rep

View full text Add to dashboard Cite

Numerous geriatric patients are using Complementary and Alternative Medicine (CAM) for late-life mood and cognitive disorders. Natural products and supplements are a common CAM intervention which have risks and benefits of which patients should be appropriately advised. The data for omega-3 fatty acids, ginkgo biloba, SAMe, St John’s wort, B Vitamins and Vitamin D, huperzine, caprylidene and coconut oil will be evaluated. Since the evidence basis for natural products and supplements is limited, especially for the geriatric population. Studies involving the general adult population are included to infer effects in the aging population. Despite the data available, more rigorous studies with larger sample sizes over longer periods of time are still needed. Regardless of a physician’s preference to recommend various natural supplements and products, a physician could protect their patients by having an understanding of the side effects and indications for various natural products.

show abstract

Treatment with Huperzine A Improves Cognition in Vascular Dementia Patients

Abstract: Huperzine A can significantly improve the cognitive function in patients with mild to moderate vascular dementia. Further, the medicament is safe.

Cited by 48 publications

References 14 publications

Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis

Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis

Vascular Contributions to Cognitive Impairment and Treatments with Traditional Chinese Medicine

Natural Products and Supplements for Geriatric Depression and Cognitive Disorders: An Evaluation of the Research

Contact Info

Product

Resources

About